Statistics & PMx

(M-020) Assessment of Drug-Drug Interaction Effect of Gastric Acid Reducing Agents on Lazertinib Exposure in EGFR-Mutated Non-Small Cell Lung Cancer

(M-042) Leveraging Real-World Data for Osteoarthritis Severity Score Modeling: An InSilicoTrials Platform Application

(M-043) Model-based meta-analysis of objective response rate and overall survival in recurrent/metastatic head and neck squamous cell carcinoma

(M-065) Pharmacometrics and Machine Learning-Based Modeling to Assess the Impact of Vaginal Microbiome on Tenofovir Exposures in the Female Genital Tract of African Women

(M-066) Model-informed Assessment of the Impact of Relaxing the high-sensitivity C-reactive protein Inclusion Criteria on Patient Enrollment and Efficacy Signal in Rheumatoid Arthritis Clinical Trial Design

(S-006) Population Pharmacokinetics and Exposure-Response Analysis for TAR-200, an Intravesical Drug Delivery System for Bladder Cancer Treatment

(S-014) Survival Modeling of Dementia Risk Using Metabolic Syndrome-Related Genetic Variants

(S-026) Evaluation of Fluctuating Drug Concentration and Pharmacokinetic Effects on Time-to-event Endpoint Using Proportional Hazard Cox Regression in NONMEM

(S-027) Implementation of Efron Correction for Tied-time Records in Time-variant and Time-invariant Cox Proportional Hazard Model in NONMEM

(S-041) A simulation-based Comparison of Approaches to Safety Outcome Estimation in Special Populations

(S-042) Full covariate model construction, usage, and reduction in population pharmacokinetics

(S-056) Quantitative Assessment of Glecaprevir and Pibrentasvir Exposures in Adults with Chronic or Acute HCV Infection: A Comprehensive Analysis of Phase 2 and 3 Studies Utilizing Subject Matching and Population PK Simulations

(S-069) Evaluation and Mitigation of Time-Dependent Confounding Effects in Conventional Exposure-Response Analyses for Small-Molecule Oncology Drugs

(S-070) Amplified Bioanalytical Uncertainty Propagation Impact on Population Pharmacokinetic Modeling

(S-071) Assessment of Virtual Control Groups for Organ Impairment Studies Using Population Pharmacokinetic Simulation: Twin Matching versus Group Matching

(S-104) Model-Informed Dose Selection for mRNA-3927 in Participants with Propionic Acidemia (PA)

(T-021) Utilizing Generative Deep Learning and Bayesian Neural Network for Pharmacometrics Covariate Analysis

(T-040) Disease progression model for TKV and eGFR prediction in patients with autosomal dominant polycystic kidney disease

(T-041) An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information

(T-058) Modeling Huntington’s disease progression utilizing the Huntington’s disease integrated staging system

(T-070) Development and External Validation of a Machine Learning Model to Predict Clearance in Patients with Epilepsy and Migraine Receiving Intravenous Topiramate with or without Enzyme-Inducing Comedications

(T-079) Population Pharmacokinetic Analysis to Characterize Pharmacokinetics of Sarilumab in Pediatric Participants with Polyarticular-Course Juvenile Idiopathic Arthritis